Rhythm outcomes after catheter ablation of atrial fibrillation

J. Kornej; D. Husser; A. Bollmann; G. Y. H. Lip

doi:10.5482/HAMO-13-09-0051

Hämostaseologie, Inhaltsverzeichnis

Hamostaseologie 2014; 34(01): 9-19
DOI: 10.5482/HAMO-13-09-0051

Review

Schattauer GmbH

Rhythm outcomes after catheter ablation of atrial fibrillation

Clinical implication of biomarkersRhythmuskontrolle nach Katheterablation von VorhofflimmernDie klinische Bedeutung der Biomarker

J. Kornej

¹University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom

²Heart Center Department of Electrophysiology, University of Leipzig, Germany

,

D. Husser

²Heart Center Department of Electrophysiology, University of Leipzig, Germany

,

A. Bollmann

²Heart Center Department of Electrophysiology, University of Leipzig, Germany

,

G. Y. H. Lip

¹University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom

› Institutsangaben

Abstract

Summary

Atrial fibrillation (AF) occurs as the result of numerous complex physiological processes in the atria leading to AF promotion and maintenance. Improved diagnostic techniques have identified various biomarkers which may play an important role in the prediction of AF related outcomes (cardio- and cerebrovascular events, as well as mortality and rhythm outcomes). Biomarkers refer to ‘biological markers’ and biomarkers in blood, urine as well as imaging marker (eg, dimensions (left atrial diameter and volume), anatomical features (left appendage and pulmonary vein anatomy), and physiological pattern (LAA flow velocity)) may play important role(s) as clinically important indices in relation to outcomes after different therapeutic strategies. However, the main domain in the biomarker field has focused on bloodbased biomarkers, which are widely used to predict therapeutic success regarding underlying pathophysiological mechanism, such as inflammation, fibrosis, endothelial damage. This review provides an update of the role of clinically relevant biomarkers in AF, with particular focus on AF rhythm outcomes.

Zusammenfassung

Verschiedene komplexe pathophysiologische Prozesse führen zu Vorhofflimmern (VHF). In den letzten Jahren konnten verschiedene Biomarker identifiziert werden, die eine Bedeutung zur Vorhersage von Morbidität (z. B. kardiovaskuläre Ereignisse), Mortalität und Rhythmuserhalt erlangen könnten. Dabei spielen Marker der Inflammation, Fibrose und endothelialen Dysfunktion ein besondere Rolle. Da diese Prozesse wesentlich den Erfolg des Rhythmuserhaltes z. B. nach Katheterablation beeinflussen, soll diese Übersichtsarbeit den aktuellen Wissenstand zu Biomarkern bei Vorhofflimmern und im speziellen zum Erhalt des Sinusrhythmus zusammenfassen und mögliche klinische Anwendungen aufzeigen.

Keywords

Atrial fibrillation - catheter ablation - recurrence - biomarkers

Schlüsselwörter

Vorhofflimmern - Katheterablation - Rezidive - Biomarker

Volltext

Referenzen

References
1 Anderson JL, Allen CAMaycock, Lappe DL. et al. Frequency of elevation of C-reactive protein in atrial fibrillation. Am J Cardiol 2004; 94: 1255-1259.
2 Bartkowiak R, Wozakowska-Kaplon B, Janiszewska G. Plasma NT-proANP in patients with persistent atrial fibrillation who underwent successful cardioversion. Kardiol Pol 2010; 68: 48-54.
3 Benjamin EJ, Rice KM, Arking DE. et al. Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestry. Nat Genet 2009; 41: 879-881.
4 Benjamin MShoemaker, Muhammad R, Parvez B. et al. Common atrial fibrillation risk alleles at 4q25 predict recurrence after catheter-based atrial fibrillation ablation. Heart Rhythm 2013; 10: 394-400.
5 Bisbal F, Guiu E, Calvo N. et al. Left atrial sphericity: A new method to assess atrial remodeling. Impact on the outcome of atrial fibrillation ablation. J Cardiovasc Electrophysiol 2013; 24: 752-759.
6 Bitter T, Nolker G, Vogt J. et al. Predictors of recurrence in patients undergoing cryoballoon ablation for treatment of atrial fibrillation: the independent role of sleep-disordered breathing. J Cardiovasc Electrophysiol 2012; 23: 18-25.
7 Blann AD. Endothelial cell activation, injury, damage and dysfunction: separate entities or mutual terms?. Blood Coagul Fibrinolysis 2000; 11: 623-630.
8 Bordignon S, Chun KR, Gunawardene M. et al. Endoscopic ablation systems. Expert Rev Med Devices 2013; 10: 177-183.
9 Buccelletti F, Gilardi E, Marsiliani D. et al. Predictive value of NT-proBNP for cardioversion in a new onset atrial fibrillation. Eur J Emerg Med 2011; 18: 157-161.
10 Camm AJ, Kirchhof P, Lip GY. et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010; 12: 1360-1420.
11 Chang SL, Tsao HM, Lin YJ. et al. Characteristics and significance of very early recurrence of atrial fibrillation after catheter ablation. J Cardiovasc Electrophysiol 2011; 22: 1193-1198.
12 Chen YH, Xu SJ, Bendahhou S. et al. KCNQ1 gainof-function mutation in familial atrial fibrillation. Science 2003; 299: 251-254.
13 Combes S, Jacob S, Combes N. et al. Predicting favourable outcomes in the setting of radiofrequency catheter ablation of long-standing persistent atrial fibrillation: A pilot study assessing the value of left atrial appendage peak flow velocity. Arch Cardiovasc Dis 2013; 106: 36-43.
14 Condorelli G, Latronico MV, Dorn 2^nd GW. microRNAs in heart disease: putative novel therapeutic targets?. Eur Heart J 2010; 31: 649-658.
15 Coppens M, Eikelboom JW, Hart RG. et al. The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. Eur Heart J 2013; 34: 170-176.
16 Daoud EG, Bogun F, Goyal R. et al. Effect of atrial fibrillation on atrial refractoriness in humans. Circulation 1996; 94: 1600-1606.
17 Davlouros PA, Simeonidou E, Tsakas S. et al. Release of endothelin-1 from human endocardium after radiofrequency catheter ablation and coronary angioplasty: comparative results. Int J Cardiol 2005; 102: 187-193.
18 Degener S, Pattberg SV, Feuersenger H. et al. Predictive value of B-type natriuretic peptide levels in patients with paroxysmal and persistent atrial fibrillation undergoing pulmonary vein isolation. J Interv Card Electrophysiol 2011; 30: 217-225.
19 den Uijl DW, Delgado V, Tops LF. et al. Natriuretic peptide levels predict recurrence of atrial fibrillation after radiofrequency catheter ablation. Am Heart J 2011; 161: 197-203.
20 Dobrev D, Nattel S. Calcium handling abnormalities in atrial fibrillation as a target for innovative therapeutics. J Cardiovasc Pharmacol 2008; 52: 293-299.
21 Doty JR, Clayson SE. Surgical treatment of isolated (lone) atrial fibrillation with Gemini-S Ablation and Left Atrial Appendage Excision (GALAXY procedure). Innovations (Phila) 2012; 07: 33-38.
22 Ellinor PT, Lunetta KL, Glazer NL. et al. Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet 2010; 42: 240-244.
23 Engelmann MD, Svendsen JH. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J 2005; 26: 2083-2092.
24 Fan J, Cao H, Su L. et al. NT-proBNP, but not ANP and C-reactive protein, is predictive of paroxysmal atrial fibrillation in patients undergoing pulmonary vein isolation. J Interv Card Electrophysiol 2012; 33: 93-100.
25 Freestone B, Chong AY, Blann AD, Lip GY. The effects of direct current cardioversion for persistent atrial fibrillation on indices of endothelial damage/ dysfunction. Thromb Res 2006; 118: 479-485.
26 Frustaci A, Chimenti C, Bellocci F. et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997; 96: 1180-1184.
27 Gonzalez-Ramos M, Calleros L, Lopez-Ongil S. et al. HSP70 increases extracellular matrix production by human vascular smooth muscle through TGF-beta1 up-regulation. Int J Biochem Cell Biol 2013; 45: 232-242.
28 Grubman E, Pavri BB, Lyle S. et al. Histopathologic effects of radiofrequency catheter ablation in previously infarcted human myocardium. J Cardio - vasc Electrophysiol 1999; 10: 336-342.
29 Gudbjartsson DF, Arnar DO, Helgadottir A. et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature 2007; 448: 353-357.
30 Hartono B, Lo LW, Cheng CC. et al. A novel finding of the atrial substrate properties and long-term results of catheter ablation in chronic atrial fibrillation patients with left atrial spontaneous echo contrast. J Cardiovasc Electrophysiol 2012; 23: 239-246.
31 He XN, Li SN, Zhan JL. et al. Serum uric acid levels correlate with recurrence of paroxysmal atrial fibrillation after catheter ablation. Chin Med J (Engl) 2013; 126: 860-864.
32 Helms AS, West JJ, Patel A. et al. Relation of left atrial volume from three-dimensional computed tomography to atrial fibrillation recurrence following ablation. Am J Cardiol 2009; 103: 989-993.
33 Henningsen KM, Therkelsen SK, Bruunsgaard H. et al. Prognostic impact of hs-CRP and IL-6 in patients with persistent atrial fibrillation treated with electrical cardioversion. Scand J Clin Lab Invest 2009; 69: 425-432.
34 Heppell RM, Berkin KE, McLenachan JM, Davies JA. Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in nonrheumatic atrial fibrillation. Heart 1997; 77: 407-411.
35 Herrera CSiklody, Arentz T. et al. Cellular damage, platelet activation, and inflammatory response after pulmonary vein isolation: a randomized study comparing radiofrequency ablation with cryoablation. Heart Rhythm 2012; 09: 189-196.
36 Hijazi Z, Oldgren J, Andersson U. et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. Circulation 2012; 125: 1605-1616.
37 Hu YF, Yeh HI, Tsao HM. et al. Electrophysiological correlation and prognostic impact of heat shock protein 27 in atrial fibrillation. Circ Arrhythm Electrophysiol 2012; 05: 334-340.
38 Hussein AA, Saliba WI, Martin DO. et al. Plasma B-type natriuretic peptide levels and recurrent arrhythmia after successful ablation of lone atrial fibrillation. Circulation 2011; 123: 2077-2082.
39 Husser D, Adams V, Piorkowski C. et al. Chromosome 4q25 variants and atrial fibrillation recurrence after catheter ablation. JACC 2010; 55: 747-753.
40 Hwang HJ, Son JW, Nam BH. et al. Incremental predictive value of pre-procedural N-terminal pro- B-type natriuretic peptide for short-term recurrence in atrial fibrillation ablation. Clin Res Cardiol 2009; 98: 213-218.
41 Inoue S, Murakami Y, Sano K. et al. Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation. J Card Fail 2000; 06: 92-96.
42 Ionescu-Ittu R, Abrahamowicz M, Kackevicius CA. et al. Comparative effectiveness of rhythm control vs rate control drug treatment effect on mortality in patients with atrial fibrillation. Arch Intern Med 2012; 172: 997-1004.
43 Issac TT, Dokainish H, Lakkis NM. Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol 2007; 50: 2021-2028.
44 Kang JH, Lee DI, Kim S. et al. Prediction of longterm outcomes of catheter ablation of persistent atrial fibrillation by parameters of preablation DC cardioversion. J Cardiovasc Electrophysiol 2012; 23: 1165-1170.
45 Katus HA, Remppis A, Neumann FJ. et al. Diagnostic efficiency of troponin T measurements in acute myocardial infarction. Circulation 1991; 83: 902-912.
46 Kerr R, Stirling D, Ludlam CA. Interleukin 6 and haemostasis. Br J Haematol 2001; 115: 3-12.
47 Kim SK, Pak HN, Park JH. et al. Clinical and serological predictors for the recurrence of atrial fibrillation after electrical cardioversion. Europace 2009; 11: 1632-1638.
48 Kim SK, Park JH, Kim JY. et al. High plasma concentrations of transforming growth factor-beta and tissue inhibitor of metalloproteinase-1: potential non-invasive predictors for electroanatomical remodeling of atrium in patients with non-valvular atrial fibrillation. Circ J 2011; 75: 557-564.
49 Kornej J, Reinhardt C, Kosiuk J. et al. Response of circulating heat shock protein 70 and anti-heat shock protein 70 antibodies to catheter ablation of atrial fibrillation. J Transl Med 2013; 11: 49.
50 Kornej J, Reinhardt C, Kosiuk J. et al. Response of high-sensitive C-reactive protein to catheter ablation of atrial fibrillation and its relation with rhythm outcome. PLoS One 2012; 07: e44165.
51 Latini R, Masson S, Pirelli S. et al. Circulating cardiovascular biomarkers in recurrent atrial fibrillation: data from the GISSI-atrial fibrillation trial. J Intern Med 2011; 269: 160-171.
52 Lellouche N, Sacher F, Wright M. et al. Usefulness of C-reactive protein in predicting early and late recurrences after atrial fibrillation ablation. Europace 2009; 11: 662-664.
53 Letsas KP, Efremidis M, Giannopoulos G. et al. CHADS2 and CHA2DS2-VASc scores as predictors of left atrial ablation outcomes for paroxysmal atrial fibrillation. Europace. 2013 doi: 10.1093/ europace/eut210.
54 Li C, Ding X, Zhang J. et al. Does the E/e’ index predict the maintenance of sinus rhythm after catheter ablation of atrial fibrillation?. Echocardiography 2010; 27: 630-636.
55 Lin YJ, Tsao HM, Chang SL. et al. Prognostic implications of the high-sensitive C-reactive protein in the catheter ablation of atrial fibrillation. Am J Cardiol 2010; 105: 495-501.
56 Lip GY. Does atrial fibrillation confer a hypercoagulable state?. Lancet 1995; 346: 1313-1314.
57 Lip GY, Nieuwlaat R, Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263-272.
58 Liu T, Li G, Li L, Korantzopoulos P. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. J Am Coll Cardiol 2007; 49: 1642-1648.
59 Manabe I, Shindo T, Nagai R. Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy. Circ Res 2002; 91: 1103-1113.
60 Marcus GM, Smith LM, Glidden DV. et al. Markers of Inflammation before and after curative ablation of atrial flutter. Heart Rhythm 2008; 05: 215-221.
61 Marin F, Roldan V, Climent V. et al. Is thrombogenesis in atrial fibrillation related to matrix metalloproteinase-1 and its inhibitor, TIMP-1?. Stroke 2003; 34: 1181-1186.
62 Marin F, Roldan V, Climent VE. et al. Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in acute onset nonrheumatic atrial fibrillation. Heart 2004; 90: 1162-1166.
63 Matsuo S, Lellouche N, Wright M. et al. Clinical predictors of termination and clinical outcome of catheter ablation for persistent atrial fibrillation. J Am Coll Cardiol 2009; 54: 788-795.
64 McCabe JM, Smith LM, Tseng ZH. et al. Protracted CRP elevation after atrial fibrillation ablation. Pacing Clin Electrophysiol 2008; 31: 1146-1151.
65 Metzner A, Wissner E, Schmidt B. et al. Acute and long-term clinical outcome after endoscopic pulmonary vein isolation: results from the first prospective, multicenter study. J Cardiovasc Electrophysiol 2013; 24: 7-13.
66 Montefusco A, Biasco L, Blandino A. et al. Left atrial volume at MRI is the main determinant of outcome after pulmonary vein isolation plus linear lesion ablation for paroxysmal-persistent atrial fibrillation. J Cardiovasc Med (Hagerstown) 2010; 11: 593-598.
67 Nakazawa Y, Ashihara T, Tsutamoto T. et al. Endothelin-1 as a predictor of atrial fibrillation recurrence after pulmonary vein isolation. Heart Rhythm 2009; 06: 725-730.
68 Nakhjavani M, Morteza A, Asgarani F. et al. The dual behavior of heat shock protein 70 and asymmetric dimethylarginine in relation to serum CRP levels in type 2 diabetes. Gene 2012; 498: 107-111.
69 Neumann T, Wojcik M, Berkowitsch A. et al. Cryoballoon ablation of paroxysmal atrial fibrillation: 5-year outcome after single procedure and predictors of success. Europace 2013; 19: 1143-1149.
70 Okumura Y, Watanabe I, Nakai T. et al. Impact of biomarkers of inflammation and extracellular matrix turnover on the outcome of atrial fibrillation ablation: importance of matrix metalloproteinase-2 as a predictor of atrial fibrillation recurrence. J Cardiovasc Electrophysiol 2011; 22: 987-993.
71 Olesen JB, Torp-Pedersen C, Hansen ML, Lip GY. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0–1: a nation- wide cohort study. Thromb Haemost 2012; 107: 1172-1179.
72 Osmancik P, Peroutka Z, Budera P. et al. Changes in cytokine concentrations following successful ablation of atrial fibrillation. Eur Cytokine Netw 2010; 21: 278-284.
73 Parvez B, Shoemaker MB, Muhammad R. et al. Common genetic polymorphism at 4q25 locus predicts atrial fibrillation recurrence after successful cardioversion. Heart Rhythm 2013; 10: 849-855.
74 Pigott R, Dillon LP, Hemingway IH, Gearing AJ. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun 1992; 187: 584-589.
75 Pison L, La MMeir, van Opstal J. et al. Hybrid thoracoscopic surgical and transvenous catheter ablation of atrial fibrillation. J Am Coll Cardiol 2012; 60: 54-61.
76 Richter B, Gwechenberger M, Socas A. et al. Markers of oxidative stress after ablation of atrial fibrillation are associated with inflammation, delivered radiofrequency energy and early recurrence of atrial fibrillation. Clin Res Cardiol 2012; 101: 217-225.
77 Richter B, Gwechenberger M, Socas A. et al. Time course of markers of tissue repair after ablation of atrial fibrillation and their relation to left atrial structural changes and clinical ablation outcome. Int J Cardiol 2011; 152: 231-236.
78 Roldan V, Marin F, Garcia-Herola A, Lip GY. Correlation of plasma von Willebrand factor levels, an index of endothelial damage/dysfunction, with two point-based stroke risk stratification scores in atrial fibrillation. Thromb Res 2005; 116: 321-325.
79 Sadanaga T, Kohsaka S, Ogawa S. D-dimer levels in combination with clinical risk factors can effectively predict subsequent thromboembolic events in patients with atrial fibrillation during oral anticoagulant therapy. Cardiology 2010; 117: 31-36.
80 Sato M, Suzuki A, Nagata K, Uchiyama S. Increased von Willebrand factor in acute stroke patients with atrial fibrillation. J Stroke Cerebrovasc Dis 2006; 15: 1-7.
81 Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev 2011; 91: 265-325.
82 Shan H, Zhang Y, Lu Y. et al. Downregulation of miR-133 and miR-590 contributes to nicotine-induced atrial remodelling in canines. Cardiovasc Res 2009; 83: 465-472.
83 Shim J, Park JH, Kim JY. et al. Impaired mobilization of bone marrow derived CD34 positive mononuclear cells is related to the recurrence of atrial fibrillation after radiofrequency catheter ablation. Int J Cardiol 2013; 162: 179-183.
84 Shin DI, Deneke T, Gorr E. et al. Predicting successful pulmonary vein isolation in patients with atrial fibrillation by brain natriuretic Peptide plasma levels. Indian Pacing Electrophysiol J 2009; 09: 241-246.
85 Shin SY, Na JO, Lim HE. et al. Improved endothelial function in patients with atrial fibrillation through maintenance of sinus rhythm by successful catheter ablation. J Cardiovasc Electrophysiol 2011; 22: 376-382.
86 Skalidis EI, Zacharis EA, Tsetis DK. et al. Endothelial cell function during atrial fibrillation and after restoration of sinus rhythm. Am J Cardiol 2007; 99: 1258-1262.
87 St Rammos K, Koullias GJ, Hassan MO. et al. Low preoperative HSP70 atrial myocardial levels correlate significantly with high incidence of postoperative atrial fibrillation after cardiac surgery. Cardiovasc Surg 2002; 10: 228-232.
88 Stefansdottir H, Arnar DO, Aspelund T. et al. Atrial fibrillation is associated with reduced brain volume and cognitive function independent of cerebral infarcts. Stroke 2013; 44: 1020-1029.
89 Swaans MJ, Alipour A, Rensing BJ. et al. Catheter ablation in combination with left atrial appendage closure for atrial fibrillation. J Vis Exp 2013; 72: e3818.
90 Tan AY, Zimetbaum P. Atrial fibrillation and atrial fibrosis. J Cardiovasc Pharmacol 2011; 57: 625-629.
91 Tveit A, Seljeflot I, Grundvold I. et al. Candesartan, NT-proBNP and recurrence of atrial fibrillation after electrical cardioversion. Int J Cardiol 2009; 131: 234-239.
92 Ueberham L, Bollmann A, Shoemaker MB. et al. Genetic ACE I/D Polymorphism and Recurrence of Atrial Fibrillation after Catheter Ablation. Circ Arrhythm Electrophysiol 2013; 06: 732-737.
93 Wang W, Liu L, Li Y. et al. Does the expression of transforming growth factor beta-1: affect the outcome of the radiofrequency modified maze procedure in patients with rheumatic atrial fibrillation?. Tex Heart Inst J 2012; 39: 17-23.
94 Wang Z, Lu Y, Yang B. MicroRNAs and atrial fibrillation: new fundamentals. Cardiovasc Res 2011; 1; 89: 710-721.
95 Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet 2009; 373: 155-166.
96 Wong CX, Abed HS, Molaee P. et al. Pericardial fat is associated with atrial fibrillation severity and ablation outcome. J Am Coll Cardiol 2011; 57: 1745-1751.
97 Wu CH, Hu YF, Chou CY. et al. Transforming growth factor-â1 level and outcome after catheter ablation for nonparoxysmal atrial fibrillation. Heart Rhythm 2013; 10: 10-15.
98 Wutzler A, Kestler C, Perrot A. et al. Variations in the human soluble epoxide hydrolase gene and recurrence of atrial fibrillation after catheter ablation. Int J Cardiol 2013; 168: 3647-3651.
99 Yalta K, Yilmaz MB, Turgut OO, Tandogan I. Natriuretic peptides: useful biomarkers in predicting the possibility of restoration and maintenance of sinus rhythm in patients with atrial fibrillation undergoing cardioversion?. Int J Cardiol 2010; 145: 233-235.
100 Yang B, Lu Y, Wang Z. Control of cardiac excitability by microRNAs. Cardiovasc Res 2008; 79: 571-580.